# Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

> **NCT00415532** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 234 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura
- Thrombocytopenia
- Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Thrombocytopenic Purpura

## Interventions

- **DRUG:** Medical Standard of Care for ITP
- **BIOLOGICAL:** Romiplostim

## Key facts

- **NCT ID:** NCT00415532
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-01
- **Primary completion:** 2008-11-07
- **Final completion:** 2009-05-11
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415532, "Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00415532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*